Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies
Language
en
Communication dans un congrès avec actes
This item was published in
DRUID Society Conf., 2016-06-13, Copenhague.
English Keywords
Innovation
Biotechnology
Orphan Drug
Patents
Initial Public Offering
Venture Capital
Origin
Hal imported